Séverine Banek

1.1k total citations · 1 hit paper
65 papers, 592 citations indexed

About

Séverine Banek is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Séverine Banek has authored 65 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 33 papers in Surgery and 18 papers in Oncology. Recurrent topics in Séverine Banek's work include Prostate Cancer Treatment and Research (25 papers), Bladder and Urothelial Cancer Treatments (24 papers) and Urinary and Genital Oncology Studies (17 papers). Séverine Banek is often cited by papers focused on Prostate Cancer Treatment and Research (25 papers), Bladder and Urothelial Cancer Treatments (24 papers) and Urinary and Genital Oncology Studies (17 papers). Séverine Banek collaborates with scholars based in Germany, Canada and United States. Séverine Banek's co-authors include Felix K.‐H. Chun, Philipp Mandel, Mike Wenzel, Luis A. Kluth, Felix Preißer, Jens Köllermann, Nadine Houédé, Yohann Loriot, Sydney Akapame and Arlene O. Siefker‐Radtke and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Séverine Banek

54 papers receiving 588 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

2023 132 citations Séverine Banek et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Séverine Banek Germany	15	290	249	162	128	99	65	592
Yuto Matsushita Japan	14	354 1.2×	237 1.0×	81 0.5×	87 0.7×	66 0.7×	74	524
Malcolm Mason United Kingdom	8	432 1.5×	257 1.0×	144 0.9×	80 0.6×	57 0.6×	14	683
Giulia Primiceri Italy	13	263 0.9×	322 1.3×	129 0.8×	58 0.5×	58 0.6×	21	571
Tatsushi Kawada Japan	12	269 0.9×	183 0.7×	82 0.5×	76 0.6×	62 0.6×	64	433
Luis Kluth Germany	15	240 0.8×	331 1.3×	113 0.7×	152 1.2×	24 0.2×	53	632
Justine Varinot France	14	175 0.6×	388 1.6×	112 0.7×	104 0.8×	39 0.4×	39	619
Naotaka Sakamoto Japan	16	250 0.9×	244 1.0×	220 1.4×	125 1.0×	37 0.4×	50	560
P. Cathcart United Kingdom	9	241 0.8×	167 0.7×	235 1.5×	44 0.3×	45 0.5×	34	613
Jae Young Joung South Korea	16	589 2.0×	287 1.2×	355 2.2×	237 1.9×	85 0.9×	83	929
Matthew D. Katz United States	9	294 1.0×	248 1.0×	86 0.5×	125 1.0×	43 0.4×	19	506

Countries citing papers authored by Séverine Banek

Since Specialization

Citations

This map shows the geographic impact of Séverine Banek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Séverine Banek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Séverine Banek more than expected).

Fields of papers citing papers by Séverine Banek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Séverine Banek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Séverine Banek. The network helps show where Séverine Banek may publish in the future.

Co-authorship network of co-authors of Séverine Banek

This figure shows the co-authorship network connecting the top 25 collaborators of Séverine Banek. A scholar is included among the top collaborators of Séverine Banek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Séverine Banek. Séverine Banek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wenzel, Mike, Benedikt Hoeh, Carolin Siech, et al.. (2025). Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. European Journal of Nuclear Medicine and Molecular Imaging. 52(6). 2015–2022. 1 indexed citations

Wenzel, Mike, Cristina Cano Garcia, Clara Humke, et al.. (2025). Cancer-control outcomes with [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patients. Theranostics. 15(7). 2672–2679. 3 indexed citations

Siech, Carolin, Mario de Angelis, Francesco Di Bello, et al.. (2024). Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival. Annals of Surgical Oncology. 31(13). 8993–9001.

Wenzel, Mike, Benedikt Hoeh, Florestan Koll, et al.. (2024). Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients. Clinical Genitourinary Cancer. 22(5). 102158–102158. 2 indexed citations

Winkelmann, Ria, Nina I. Becker, Peter J. Wild, et al.. (2024). Gene Expression Profiling of the Peritumoral Immune Cell Infiltrate of Penile Squamous Cell Carcinomas. International Journal of Molecular Sciences. 25(22). 12142–12142.

Garcia, Cristina Cano, Benedikt Hoeh, Séverine Banek, et al.. (2024). First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany. Clinical Genitourinary Cancer. 22(4). 102112–102112. 3 indexed citations

Wenzel, Mike, Florestan Koll, Benedikt Hoeh, et al.. (2024). Real-World Comparison of Cabazitaxel Versus¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 66(1). 61–66. 3 indexed citations

Wenzel, Mike, Benedikt Hoeh, Florestan Koll, et al.. (2024). Impact of homologous recombination repair/BReast CAncer ( BRCA ) gene alterations on survival in a real‐world setting of metastatic prostate cancer. British Journal of Urology. 135(1). 117–124. 5 indexed citations

Klümper, Niklas, Thomas Büttner, Alexander Höllein, et al.. (2024). Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.. Journal of Clinical Oncology. 42(4_suppl). 553–553. 1 indexed citations

10.

Garcia, Cristina Cano, Francesco Barletta, Stefano Tappero, et al.. (2024). Regional Differences in Stage III Nonseminoma Germ Cell Tumor Patients Across SEER Registries. Clinical Genitourinary Cancer. 22(5). 102161–102161. 1 indexed citations

11.

Koll, Florestan, Séverine Banek, Luis Kluth, et al.. (2023). Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis. Journal of Translational Medicine. 21(1). 124–124. 25 indexed citations

12.

Hoeh, Benedikt, Cristina Cano Garcia, Séverine Banek, et al.. (2023). Early CRP kinetics to predict long‐term efficacy of first‐line immune‐checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real‐world experience applying different CRP kinetics definitions. Clinical & Translational Immunology. 12(10). e1471–e1471. 7 indexed citations

13.

Banek, Séverine, Benedikt Hoeh, Cristina Cano Garcia, et al.. (2023). Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies. Urologia Internationalis. 108(1). 1–8. 8 indexed citations

14.

Garcia, Cristina Cano, Francesco Barletta, Reha‐Baris Incesu, et al.. (2023). Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages. Cancers. 15(3). 694–694. 1 indexed citations

15.

Hoeh, Benedikt, Niklas Klümper, Oliver Hahn, et al.. (2022). Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Urologia Internationalis. 106(11). 1150–1157. 7 indexed citations

16.

Hoeh, Benedikt, Mike Wenzel, Felix Preißer, et al.. (2022). Comparison of survival outcomes between laparoscopic versus open radical nephroureterectomy in upper tract urothelial cancer patients: Experiences of a tertiary care single center. Current Urology. 17(4). 292–298. 3 indexed citations

17.

Wenzel, Mike, Claudia Collà Ruvolo, Christoph Würnschimmel, et al.. (2022). Epidemiology of Unconventional Histological Subtypes of Urethral Cancer. Urologia Internationalis. 107(1). 15–22.

18.

Deuker, Marina, Pierre I. Karakiewicz, Luis A. Kluth, et al.. (2020). Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy. World Journal of Urology. 39(4). 1219–1226. 16 indexed citations

19.

Horstmann, Marcus, Séverine Banek, Georgios Gakis, et al.. (2014). Prospective evaluation of fluorescence-guided cystoscopy to detect bladder cancer in a high-risk population: results from the UroScreen-Study. SpringerPlus. 3(1). 24–24. 6 indexed citations

20.

Johnen, Georg, Katarzyna Gawrych, Beate Pesch, et al.. (2012). Performance of Survivin mRNA as a Biomarker for Bladder Cancer in the Prospective Study UroScreen. PLoS ONE. 7(4). e35363–e35363. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact